Experimental Evidence and Clinical Implications of Pituitary Adenoma Stem Cells
Pituitary adenomas, accounting for 15% of diagnosed intracranial neoplasms, are usually benign and pharmacologically and surgically treatable; however, the critical location, mass effects and hormone hypersecretion sustain their significant morbidity. Approximately 35% of pituitary tumors show a les...
Main Authors: | Roberto Würth, Stefano Thellung, Alessandro Corsaro, Federica Barbieri, Tullio Florio |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-02-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fendo.2020.00054/full |
Similar Items
-
Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System
by: Federica Barbieri, et al.
Published: (2014-01-01) -
Emerging Role of Cellular Prion Protein in the Maintenance and Expansion of Glioma Stem Cells
by: Stefano Thellung, et al.
Published: (2019-11-01) -
Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies
by: Adriana Bajetto, et al.
Published: (2020-11-01) -
Acromegaly with no pituitary adenoma and no evidence of ectopic source
by: Deepak Khandelwal, et al.
Published: (2011-01-01) -
Identification of genes differentially expressed between a somatotrope and a lactotrope pituitary cell lines by representational difference analysis
by: Mireille Delhase
Published: (2021-09-01)